Rasagiline, a selective monoamine oxidase type B inhibitor, may be effective in early Parkinson disease (PD), according to the results of a randomized, double-blind, placebo-controlled trial reported in the December issue of the Archives of Neurology.
This treatment is really intended for people who are not at the point where they need the big guns,? lead author Andrew Siderowf, MD, told Medscape. ?The thing that separates it is its tolerability and ease of use.?
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!